Latest hire in a series reinforces the bank’s offering in the
NEW YORK--(BUSINESS WIRE)--Jul. 25, 2017--
Deutsche Bank today announced the hiring of Glen Santangelo to lead US
Equity Research coverage of the Healthcare Technology & Distribution
sector. Today’s announcement rounds out a year-long investment in
Healthcare at Deutsche Bank.
“Over the past year, we have invested strategically and significantly in
our Healthcare research platform,” said Steve Pollard, Deutsche Bank
Global Head of Equity Research. “Our platform now offers clients
comprehensive Healthcare research coverage designed to match their
sector needs with an ability to generate unique market insight.”
“Healthcare is a clear area of investment across CIB in the Americas,”
added Mark Fedorcik, co-head of Americas CIB. “We are committed to
making hires that reinforce our client offering and position us well in
this active sector.”
Glen Santangelo will join the bank in July as a Managing Director.
Santangelo has more than 20 years of experience in healthcare research
and joins from Credit Suisse where he was US Co-Director of Research.
Prior to that, he led the Credit Suisse Healthcare team and was named to
the Institutional Investor All-American Research Team for seven
consecutive years beginning in 2009. He received his BS in Accounting
from Villanova University and his MBA from New York University.
Santangelo will be based in New York and report to Steve Pollard.
Over the past twelve months, the bank has also hired Chris Rigg to cover
Healthcare Services, Dan Leonard to cover Life Science & Diagnostics
Tools, and Andrew Peters and Navin Jacob to cover Biotechnology. The
analysts all report to Steve Pollard.
Navin Jacob and Andrew Peters joined Deutsche Bank in March 2017 and May
2016, respectively, as Directors to cover the US Biotechnology sector.
Prior to joining Deutsche Bank, Jacob was a senior analyst covering
Global Pharmaceuticals at Healthcor Management and earlier covered US
Biotech & Pharmaceuticals at Citadel Asset Management. Jacob received
his BA in Biochemistry at Cornell University. He is based in New York.
Prior to joining, Peters was a Director and led the Small & Mid Cap
Biotechnology franchise at UBS. Peters received his Master of Bioscience
and MBA from Claremont McKenna College. He is based in San Francisco.
Chris Rigg joined Deutsche Bank in January 2017 as a Director and equity
research analyst covering the Healthcare Facilities & Managed Care
sector. Prior to joining Deutsche Bank, Rigg was a senior Managed Care &
Healthcare Facilities analyst at Susquehanna Financial Group and was
named one of Institutional Investor’s ‘Rising Stars of Wall
Street.’ Rigg received his BA in Business Administration and History
from Muhlenberg College and his MBA from New York University. He is
based in New York.
Dan Leonard joined Deutsche Bank in September 2016 as a Director and
equity research analyst covering the Life Science & Diagnostic Tools
sector. Prior to joining Deutsche Bank, Leonard was a senior Life
Science and Diagnostic Tools analyst at Leerink Partners. Leonard
received his MBA with Honors from The Booth School of Business at the
University of Chicago and his BA in Economics with Distinction from the
University of Michigan. He is based in New York.
The investment in US Equity Research has been complemented with new
hires in Investment Banking. Deutsche Bank recently announced the hiring
of Phillip Pucciarelli as a Managing Director and Co-Head of Americas
Healthcare Investment Banking, alongside Ross Hammerman who joined the
bank in July 2016. It also hired Robert Verdier as a Managing Director
in Healthcare Services, Nick Richitt as a Managing Director focused on
Healthcare IT and Outsourcing, William White as a Managing Director and
Head of US Life Sciences, Glenn Rewick as a Managing Director in M&A
focused on Healthcare, and Matt Jackson as a Director focused on
About Deutsche Bank
Deutsche Bank provides commercial and investment banking, retail
banking, transaction banking and asset and wealth management products
and services to corporations, governments, institutional investors,
small and medium-sized businesses, and private individuals. Deutsche
Bank is Germany’s leading bank, with a strong position in Europe and a
significant presence in the Americas and Asia Pacific.
This release contains forward-looking statements. Forward-looking
statements are statements that are not historical facts; they include
statements about our beliefs and expectations and the assumptions
underlying them. These statements are based on plans, estimates and
projections as they are currently available to the management of
Deutsche Bank. Forward-looking statements therefore speak only as of the
date they are made, and we undertake no obligation to update publicly
any of them in light of new information or future events.
By their very nature, forward-looking statements involve risks and
uncertainties. A number of important factors could therefore cause
actual results to differ materially from those contained in any
forward-looking statement. Such factors include the conditions in the
financial markets in Germany, in Europe, in the United States and
elsewhere from which we derive a substantial portion of our revenues and
in which we hold a substantial portion of our assets, the development of
asset prices and market volatility, potential defaults of borrowers or
trading counterparties, the implementation of our strategic initiatives,
the reliability of our risk management policies, procedures and methods,
and other risks referenced in our filings with the U.S. Securities and
Exchange Commission. Such factors are described in detail in our SEC
Form 20-F of 11 March 2016 under the heading “Risk Factors”. Copies of
this document are readily available upon request or can be downloaded
View source version on businesswire.com:
Source: Deutsche Bank
Press and Media Relations
Tracy McNamara, +1 212